During the past decade, Berks Hematology Oncology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Berks Hematology Oncology" #1 collaborator was "ICON Clinical Research" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Berks Hematology Oncology" are "Breast Cancer" (2 trials), "Chronic Myeloid Leukemia" (1 trials), "First or Second Line HER2-negative Breast Cancer" (1 trials) and "Metastatic Disease Without Bone Metastasis" (1 trials). Many other conditions were trialed in "Berks Hematology Oncology" in a lesser frequency.

Most popular intervention types in "Berks Hematology Oncology" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (1 trials), "Neratinib" (1 trials), "Standard Therapy" (1 trials), "Zoledronic acid" (1 trials) and "letrozole" (1 trials). Other intervention names were less common.

The vast majority of trials in "Berks Hematology Oncology" are 2 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Berks Hematology Oncology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Berks Hematology Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Berks Hematology Oncology, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".